SINOPIA BIOSCIENCES INC
- SAN DIEGO, CA 92121-1126
- Corporate Entity (Not Tax Exempt)
- SAM active
- No verified credentials yet
- CMMCNot on file
- SPRSNone
- FCLVisible to paid members
Registration and small-business types: SAM.gov, synced Nov 9, 2026. Compliance: self-attested by the company unless marked verified. The SPRS chip shows a range, never the exact score. How verification works
- 36-mo obligations
- $0
- Awards on record
- 0
- Contract vehicles
- 0
- Verified credentials
- 0
Compliance posture: unverified (SAM.gov baseline only)
SINOPIA BIOSCIENCES INC has not claimed this profile. What you see comes from public SAM.gov and USAspending records; no one from the company has confirmed CMMC, SPRS or clearance details yet. Learn more about CMMC 2.0
About SINOPIA BIOSCIENCES INC
- Headquarters
- SAN DIEGO, CA 92121-1126
Identifiers
UEI and CAGE come from SAM.gov. Other identifiers are listed by the company.
- UEIYAZGZHHKK821
- CAGE6T1Y7
Capabilities & differentiators
No capability narrative yet
Compliance posture
No compliance posture published yet
Facility clearance
Facility clearance: visible to paid members
Clearance levels are shown only to paying members; TeamingIndex does not advertise clearances (NISPOM 32 CFR 117.9). Learn more about facility clearances · Compare plans
Past performance
No federal prime awards on record
Contract vehicles
No contract vehicles on file
Proven teaming graph
No sub-award reports yet
Source: USAspending.gov sub-award reports (FSRS) (opens in a new tab) · sync date not recorded · Prime contractors report first-tier subcontracts of $30,000 or more. Amounts are reported sub-award values.
SBIR/STTR portfolio
SBIR/STTR awardee — Phase III-eligible for work derived from its SBIR/STTR projects
Agencies may award follow-on Phase III work without a new competition when it builds on this company’s earlier SBIR/STTR projects. Other work is competed as usual.
- Awards on record
- 16 awards
- Total awarded
- $15,103,899
- By phase
- SBIR Phase I: 10
- SBIR Phase II: 6
- By agency
- Department of Health and Human Services: 16
- Active projects
- 1 project
- Projects whose contract end date is today or later.
- Phase II ending within 12 months
- 0 projects
- Phase II projects ending within 12 months. Agencies may award Phase III work without a new competition only when it derives from, extends or completes these projects.
- By year
- 2025: 2
- 2024: 2
- 2023: 1
- 2022: 1
- 2021: 2
- 2019: 2
- 2018: 1
- 2017: 1
- 2016: 2
- 2015: 1
- 2014: 1
Awards (most recent first)
Development of a metabolomics enabled AI/ML platform for discovery of new treatments to enhance drug sensitivity in cancer
SBIR Phase I · Department of Health and Human Services (National Institutes of Health) · 2025 · $285,599
Sep 22, 2025 – Aug 31, 2027
- Active
Solicitation PA24-245 (2024) · Topic 102
Development of neural network models to enable efficient metabolomic characterization of compound libraries for data-driven drug discovery
SBIR Phase I · Department of Health and Human Services (National Institutes of Health) · 2025 · $350,000
Aug 1, 2025 – Jul 31, 2026
Solicitation PA24-245 (2024) · Topic 300
Preclinical assessment of a novel compound for treating radiation-induced oral mucositis
SBIR Phase II · Department of Health and Human Services (National Institutes of Health) · 2024 · $2,382,478
Sep 5, 2024 – Aug 31, 2026
Solicitation PA20-272 (2020) · Topic NIDCR
Development and validation of data standards and computational methods for large scale metabolomics data analysis for data driven drug discovery
SBIR Phase I · Department of Health and Human Services (National Institutes of Health) · 2024 · $350,000
May 1, 2024 – Apr 30, 2025
Solicitation PA23-230 (2023) · Topic 400
Preclinical development of a novel therapeutic for Parkinson's disease
SBIR Phase II · Department of Health and Human Services (National Institutes of Health) · 2023 · $2,844,059
Mar 1, 2023 – Feb 28, 2025
Solicitation PA20-260 (2020) · Topic 106
Preclinical assessment of a novel compound for treating radiation-induced oral mucositis
SBIR Phase I · Department of Health and Human Services (National Institutes of Health) · 2022 · $318,284
Sep 20, 2022 – Sep 19, 2023
Solicitation PA21-259 (2021) · Topic 100
Preclinical development of a novel therapeutic for Parkinson's disease
SBIR Phase I · Department of Health and Human Services (National Institutes of Health) · 2021 · $577,562
Sep 30, 2021 – Jun 30, 2022
Solicitation PA20-260 (2020) · Topic 106
Development of a metabolomics and machine learning based high-throughput screening platform for data-driven drug discovery
SBIR Phase II · Department of Health and Human Services (National Institutes of Health) · 2021 · $2,207,584
Feb 5, 2021 – Jan 31, 2023
Solicitation PA19-272 (2019) · Topic 400
Developing a systems biology platform for predicting, preventing, and treating drug side effects
SBIR Phase II · Department of Health and Human Services (National Institutes of Health) · 2019 · $1,557,016
May 1, 2019 – Apr 30, 2021
Solicitation PA18-574 (2018) · Topic 400
Improving safety and efficacy of platelet pathogen inactivation techniques through systems biology
SBIR Phase I · Department of Health and Human Services (National Institutes of Health) · 2019 · $224,284
Apr 1, 2019 – Sep 30, 2020
Solicitation PA18-574 (2018) · Topic NHLBI
Development of a metabolomics and machine learning based high-throughput screening platform for data-driven drug discovery
SBIR Phase I · Department of Health and Human Services (National Institutes of Health) · 2018 · $442,427
Sep 1, 2018 – Aug 31, 2019
Solicitation PA17-302 (2017) · Topic 400
Improving safety and efficacy of platelet transfusion through systems biology
SBIR Phase II · Department of Health and Human Services (National Institutes of Health) · 2017 · $1,527,749
Jun 15, 2017 – Mar 31, 2020
Solicitation PA16-302 (2016) · Topic NHLBI
Developing a Systems Biology Platform for Predicting Drug Toxicity and Safety
SBIR Phase I · Department of Health and Human Services (National Institutes of Health) · 2016 · $190,634
Sep 15, 2016 – May 14, 2018
Solicitation PA14-154 (2014) · Topic 300
Improving red blood cell transfusion through systems biology
SBIR Phase II · Department of Health and Human Services (National Institutes of Health) · 2016 · $1,472,641
Aug 15, 2016 – May 31, 2019
Solicitation PA14-071 (2014) · Topic NHLBI
Improving safety and efficacy of platelet transfusion through systems biology
SBIR Phase I · Department of Health and Human Services (National Institutes of Health) · 2015 · $223,582
Aug 1, 2015 – Jul 31, 2016
Solicitation PA14-071 (2015) · Topic NHLBI
Improving red blood cell transfusion through systems biology
SBIR Phase I · Department of Health and Human Services (National Institutes of Health) · 2014 · $150,000
Solicitation PAR09-220 (2014) · Topic NHLBI · Research partner: Stub
Source: SBIR.gov award data file (opens in a new tab) · as of Nov 12, 2026 · file published Nov 1, 2026
FedRAMP offerings
No FedRAMP Marketplace listing
Source: FedRAMP Marketplace (opens in a new tab) · sync date not recorded
Exclusions & screening
SAM.gov exclusions
No active exclusion on record (checked Nov 14, 2026).
Agencies generally may not award to excluded parties, and primes may not subcontract with them above the threshold in FAR 52.209-6 (except COTS items) without a compelling reason reported to the contracting officer (FAR 9.405, 9.405-2). Some exclusion types apply only to specific programs: read the record on SAM.gov.
Source: SAM.gov Exclusions (opens in a new tab) · as of Nov 14, 2026
Consolidated Screening List
No confirmed match on the Consolidated Screening List (screened Nov 14, 2026).
The list combines Commerce, State and Treasury export-control and sanctions lists. A “no match” result is a name-and-address screen, not an export-compliance determination.
Source: ITA Consolidated Screening List (opens in a new tab) · as of Nov 14, 2026
GSA CALC+ rate benchmark
No GSA CALC+ rates on record
Source: GSA CALC+ awarded ceiling rates (opens in a new tab) · sync date not recorded
NAICS, PSC & socio-economic status
NAICS codes
- 541714Research and Development in Biotechnology (except Nanobiotechnology)Primary
SAM.gov does not report this entity as small under any listed NAICS code.
Socio-economic status
No socio-economic certifications reported in SAM.gov.
Product & service codes (PSC)
No PSC codes reported.
Teaming preferences
This company has not published teaming preferences.
Business development contact
No BD contact published
Corporate hierarchy
No parent entity reported in SAM.gov.
SBA counts affiliates when it determines whether a business is small (13 CFR 121.103), so a parent’s size can matter for set-aside work.
Data sources & provenance
SAM.gov
Registration, CAGE, NAICS, socio-economic status, corporate hierarchy and exclusions. Last synced Nov 9, 2026.
USAspending.gov
Prime award history and obligations (FPDS), synced nightly.
The contractor
Nothing yet: this profile has not been claimed by the company.
TeamingIndex verification
Credentials marked Verified were checked by a TeamingIndex reviewer; everything else is self-attested.
Corrections
Corrections to SAM.gov data must be made in SAM.gov; TeamingIndex picks them up on the next nightly sync. Go to SAM.gov (opens in a new tab)
Machine-readable: capability.md schema.org JSON-LD embedded in this page.
Zero CUI: TeamingIndex stores verification metadata only, never System Security Plans, POA&Ms or DD Form 254s.
Teaming
Ready to team with SINOPIA BIOSCIENCES INC?
Send an introduction and propose a mutual NDA. Their team is notified right away, and you can share the capability statement with your capture team.